<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481453</url>
  </required_header>
  <id_info>
    <org_study_id>C12-66</org_study_id>
    <secondary_id>2013-003485-14</secondary_id>
    <nct_id>NCT02481453</nct_id>
  </id_info>
  <brief_title>Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis</brief_title>
  <acronym>RAPAMI</acronym>
  <official_title>Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients&#xD;
      over 50. It is a slowly progressive, but today untreatable (notably by classical&#xD;
      immunosuppressants) disease.&#xD;
&#xD;
      Rapamycin used in organ transplantation blocks the activity of T effector cells, preserves T&#xD;
      regulatory cells and induces autophagy (protein degradation), all parameters impaired during&#xD;
      IBM.&#xD;
&#xD;
      RAPAMI is a prospective, randomised, controlled, double blind, monocentric, phase IIb trial&#xD;
      evaluating rapamycine against placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2015</start_date>
  <completion_date type="Actual">January 22, 2018</completion_date>
  <primary_completion_date type="Actual">January 22, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stabilization of quadiceps strength measured by myometry</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>stabilization of hand grip strength measured by myometry</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of 6 minutes walking test</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite measure of the handicap</measure>
    <time_frame>52 weeks</time_frame>
    <description>Rivermead Mobility Index (RMI), scale Walton, Inclusion Body Myositis Weakness Composite Index (IBMWCI), Inclusion Body Myositis Functional rating scale (IBMFRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by different scales</measure>
    <time_frame>52 weeks</time_frame>
    <description>Health Assessment Questionnaire (HAQ), Instrumental activities of daily living (IADL),Individualized Neuromuscular Quality of Life Questionnaire (INQol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measures of muscle fatty replacement by MRI</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the tolerance</measure>
    <time_frame>52 weeks</time_frame>
    <description>Efficacy will be measured by:&#xD;
check list of the known side effect of rapamycin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of inflammation by MRI</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Inclusion Body Myositis (IBM)</condition>
  <arm_group>
    <arm_group_label>Rapamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rapamycin 1 mg/ml oral solution, 2 mg/day (2 ml/day), once a day, during one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral solution, 2 ml/day, once a day, during one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo</description>
    <arm_group_label>Rapamycin</arm_group_label>
    <other_name>Sirolimus</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparator: placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Phosal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IBM defined by the Benveniste &amp; Hilton-Jones ( Neuromuscul Disord. 2010;20: 414-21) or&#xD;
             Llyod criteria (Neurology 2014; 83: 426-433)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossiblility to walk 10 meters&#xD;
&#xD;
          -  Hypersensitivity to rapamycin or one compound of the oral solution&#xD;
&#xD;
          -  Severe respiratory insufficiency (FVC &lt; 50% and/or FEV1 &lt; 50%)&#xD;
&#xD;
          -  Severe chronic kidney disease (Estimated Glomerular Filtration Rate &lt; 15 ml/min and/or&#xD;
             proteinuria &gt; 0.3 g/24h)&#xD;
&#xD;
          -  Chronic liver disease (cirrhosis and/or ALT/AST &gt; 2.5 normal values)&#xD;
&#xD;
          -  Cancer non in remission (necessitating specific treatment) during the past 12 months&#xD;
&#xD;
          -  Connective Tissue Disease non in remission (necessitating specific treatment) during&#xD;
             the past 12 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Seropositivity for HIV, HCV or HBV&#xD;
&#xD;
          -  Total cholesterolemia &gt; 8 mmol/l&#xD;
&#xD;
          -  Triglyceridemia &gt; 5 mmol/l&#xD;
&#xD;
          -  Hemoglobinemia &lt; 11 g/dL&#xD;
&#xD;
          -  Thrombopenia &lt; 100 000/mm3&#xD;
&#xD;
          -  Neutropenia &lt; 1500/ mm3&#xD;
&#xD;
          -  Lymphopenia &lt; 1000/ mm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CIC Paris Est _Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord. 2010 Jun;20(6):414-21. doi: 10.1016/j.nmd.2010.03.014. Epub 2010 Apr 21.</citation>
    <PMID>20413309</PMID>
  </reference>
  <reference>
    <citation>Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014 Jul 29;83(5):426-33. doi: 10.1212/WNL.0000000000000642. Epub 2014 Jun 27. Review.</citation>
    <PMID>24975859</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Myositis, Inclusion Body</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

